Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000822193 | SCV000962984 | benign | Tuberous sclerosis 2 | 2024-06-10 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001772137 | SCV002003540 | uncertain significance | not provided | 2021-04-12 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000822193 | SCV002040848 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002332711 | SCV002633966 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-07-20 | criteria provided, single submitter | clinical testing | The p.R1570K variant (also known as c.4709G>A), located in coding exon 36 of the TSC2 gene, results from a G to A substitution at nucleotide position 4709. The arginine at codon 1570 is replaced by lysine, an amino acid with highly similar properties. This variant has been detected in multiple individuals with no reported features of TSC2-associated disease (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |